↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
argenx pays **$120M** for Forte's Phase 2 dermatology asset, marking the third immunology consolidation this quarter as FcRn platforms acquire pre-biosimilar diversification.
$120 million
The Amsterdam-based immunology specialist is acquiring all outstanding shares…
$3.00 per share
in cash
42% premium
to Forte's previous closing price
19.9%
stake prior to the offer
argenx commenced a tender offer for Forte Biosciences this morning, valuing the clinical-stage dermatology company at approximately $120 million. The Amsterdam-based immunology specialist is acquiring all outstanding shares of Forte at $3.00 per share in cash, representing a 42% premium to Forte's previous closing price. The tender expires January 24, 2025, with argenx holding a 19.9% stake prior to the offer.
Forte brings FB-102, a Phase 2 asset targeting atopic dermatitis through a novel IL-12/23 inhibition mechanism. The molecule completed a 200-patient trial in moderate-to-severe AD patients in Q3 2024, with topline data showing 58% EASI-75 response at week 16 versus 31% placebo. argenx's existing portfolio centers on efgartigimod, an FcRn antagonist generating €487 million in 2024 revenue across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy indications. The Forte acquisition marks argenx's first dermatology entry and third clinical-stage bolt-on since 2022.
The timing reflects sector-wide pressure on clinical-stage dermatology firms. Forte's enterprise value contracted 67% from its January 2024 peak following slower-than-projected enrollment in a planned FB-102 psoriasis study. argenx's balance sheet held €2.1 billion in cash at September 30, providing acquisition capacity without equity dilution. The tender structure bypasses Forte's board, though major shareholders representing 34% of shares tendered support agreements. argenx plans to integrate FB-102 into its existing EU regulatory infrastructure, potentially compressing the timeline to a 2027 EU filing by 8-12 months versus Forte's standalone path.
This consolidation accelerates a pattern visible across immunology platforms. Companies with single approved FcRn or cytokine-blocking assets are acquiring earlier-stage programs to defend against 2027-2029 biosimilar erosion. argenx's efgartigimod faces potential Sandoz and Amgen biosimilars by late 2028 under current FDA timelines. Adding a differentiated IL-12/23 mechanism in a $8.4 billion atopic dermatitis market provides revenue diversification ahead of that cliff. The Forte deal also eliminates a potential competitor in the EU dermatology tender process, where health systems are consolidating rare immunology spend into fewer vendor relationships.
Allocators should monitor three developments through Q1 2025. First, whether the tender reaches the 90% threshold argenx requires to execute a short-form merger and delist Forte by February. Second, any competing bids from dermatology-focused acquirers, particularly those seeking IL-12/23 assets after AbbVie's Skyrizi dominance in psoriasis. Third, argenx's updated 2025 guidance, expected in the March earnings call, which will clarify FB-102 development spend and any revenue acceleration assumptions for efgartigimod in existing indications. The company has previously guided to positive operating cash flow by 2026; this acquisition likely extends that timeline by 2-3 quarters.
The tender closes before the February FDA advisory committee calendar is published, but the deal does not hinge on near-term regulatory events. argenx is buying optionality, not certainty.
Branded by POPS4 · proof in 60 seconds
For the principal
This signals immunology platforms are acquiring diversification 18-24 months earlier than prior cycles; review exposure to single-asset biotech holdings before biosimilar cliffs materialize.
For the operator
Watch for follow-on dermatology tenders in Q1; clinical-stage IL-12/23 and JAK programs with Phase 2 data trading below $200M enterprise value are now in-play assets.
For the house
Short interest in clinical-stage dermatology names below $300M market cap; pair long positions in acquirers with €2B+ cash and approved FcRn or cytokine franchises facing 2027-2029 erosion.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.